European Neuropsychopharmacology
Volume 22, Issue 2 , Pages 92-99, February 2012

Concomitant blockade of 5-HT1A receptor and 5-HT transporter: Use of the Hunter Serotonin Toxicity Criteria in a clinical pharmacology study

  • V. Parks

      Affiliations

    • Early Development and Clinical Pharmacology, Wyeth Research, Paris, France
    • Corresponding Author InformationCorresponding author at: Early Development & Clinical Pharmacology, Pfizer Global Research and Development, Coeur Défense — Tour A — La Défense 4, 92931 Paris La Defense Cedex, France. Tel.: +33 6 14 45 56 03; fax: +33 1 4102 7441.
    • Now at Pfizer Global Research and Development, Paris, France.
  • ,
  • A.W. Philipp

      Affiliations

    • VasoTissue Technologies, Berlin, Germany
    • Formerly at Icon Development Solutions, Manchester, United Kingdom.
  • ,
  • S. Raje

      Affiliations

    • Pfizer Inc., Collegeville, PA, USA
  • ,
  • A. Plotka

      Affiliations

    • Pfizer Inc., Collegeville, PA, USA
  • ,
  • L.E. Schechter

      Affiliations

    • Pfizer Inc., Groton, CT, USA
  • ,
  • J. Connell

      Affiliations

    • Icon Development Solutions, Manchester, United Kingdom
  • ,
  • S. Chalon

      Affiliations

    • Early Development and Clinical Pharmacology, Wyeth Research, Paris, France
    • Now at Pfizer Global Research and Development, Paris, France.

Received 2 April 2011; received in revised form 24 May 2011; accepted 10 June 2011. published online 06 July 2011.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0924-977X(11)00131-3

doi:10.1016/j.euroneuro.2011.06.002

European Neuropsychopharmacology
Volume 22, Issue 2 , Pages 92-99, February 2012